The Glucose Ketone Index Calculator: a Simple Tool to Monitor Therapeutic Efficacy for Metabolic Management of Brain Cancer

Overview

Journal Nutr Metab (Lond)

Publisher Biomed Central

Date 2015 Mar 24

PMID 25798181

Citations 46

Authors

Joshua J Meidenbauer

Purna Mukherjee

Thomas N Seyfried

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic therapy using ketogenic diets (KD) is emerging as an alternative or complementary approach to the current standard of care for brain cancer management. This therapeutic strategy targets the aerobic fermentation of glucose (Warburg effect), which is the common metabolic malady of most cancers including brain tumors. The KD targets tumor energy metabolism by lowering blood glucose and elevating blood ketones (β-hydroxybutyrate). Brain tumor cells, unlike normal brain cells, cannot use ketone bodies effectively for energy when glucose becomes limiting. Although plasma levels of glucose and ketone bodies have been used separately to predict the therapeutic success of metabolic therapy, daily glucose levels can fluctuate widely in brain cancer patients. This can create difficulty in linking changes in blood glucose and ketones to efficacy of metabolic therapy.

Methods: A program was developed (Glucose Ketone Index Calculator, GKIC) that tracks the ratio of blood glucose to ketones as a single value. We have termed this ratio the Glucose Ketone Index (GKI).

Results: The GKIC was used to compute the GKI for data published on blood glucose and ketone levels in humans and mice with brain tumors. The results showed a clear relationship between the GKI and therapeutic efficacy using ketogenic diets and calorie restriction.

Conclusions: The GKIC is a simple tool that can help monitor the efficacy of metabolic therapy in preclinical animal models and in clinical trials for malignant brain cancer and possibly other cancers that express aerobic fermentation.

Citing Articles

Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study.

Kiryttopoulos A, Evangeliou A, Katsanika I, Boukovinas I, Foroglou N, Zountsas B Front Nutr. 2025; 11:1489812.

PMID: 40041752 PMC: 11876051. DOI: 10.3389/fnut.2024.1489812.

Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.

Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.

PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.

Oral Administration of a Novel, Synthetic Ketogenic Compound Elevates Blood β-Hydroxybutyrate Levels in Mice in Both Fasted and Fed Conditions.

Soliven M, Rogers C, Williams M, Thomas N, Turos E, DAgostino D Nutrients. 2024; 16(20).

PMID: 39458521 PMC: 11510390. DOI: 10.3390/nu16203526.

Systematic Review and Clinical Insights: The Role of the Ketogenic Diet in Managing Glioblastoma in Cancer Neuroscience.

Valerio J, Borro M, Proietti E, Pisciotta L, Olarinde I, Fernandez Gomez M J Pers Med. 2024; 14(9).

PMID: 39338183 PMC: 11433106. DOI: 10.3390/jpm14090929.

Metabolic Contrasts: Fatty Acid Oxidation and Ketone Bodies in Healthy Brains vs. Glioblastoma Multiforme.

Tamas C, Tamas F, Kovecsi A, Cehan A, Balasa A Int J Mol Sci. 2024; 25(10).

PMID: 38791520 PMC: 11122426. DOI: 10.3390/ijms25105482.

References

Hartman A, Vining E . Clinical aspects of the ketogenic diet. Epilepsia. 2007; 48(1):31-42. DOI: 10.1111/j.1528-1167.2007.00914.x. View

Armstrong G, Phillips P, Rorke-Adams L, Judkins A, Russell Localio A, Fisher M . Gliomatosis cerebri: 20 years of experience at the Children's Hospital of Philadelphia. Cancer. 2006; 107(7):1597-606. DOI: 10.1002/cncr.22210. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Warburg O . On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-70. View

Sipe J, Herman M, Rubinstein L . Electron microscopic observations on human glioblastomas and astrocytomas maintained in organ culture systems. Am J Pathol. 1973; 73(3):589-606. PMC: 1904091. View

Klement R, Kammerer U . Is there a role for carbohydrate restriction in the treatment and prevention of cancer?. Nutr Metab (Lond). 2011; 8:75. PMC: 3267662. DOI: 10.1186/1743-7075-8-75. View

Shelton L, Huysentruyt L, Mukherjee P, Seyfried T . Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro. 2010; 2(3):e00038. PMC: 2908744. DOI: 10.1042/AN20100002. View

Maalouf M, Rho J, Mattson M . The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev. 2008; 59(2):293-315. PMC: 2649682. DOI: 10.1016/j.brainresrev.2008.09.002. View

Meidenbauer J, Ta N, Seyfried T . Influence of a ketogenic diet, fish-oil, and calorie restriction on plasma metabolites and lipids in C57BL/6J mice. Nutr Metab (Lond). 2014; 11:23. PMC: 4047269. DOI: 10.1186/1743-7075-11-23. View

10.

Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon M . Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res. 1997; 17(3C):1903-11. View

11.

Arismendi-Morillo G, Castellano-Ramirez A . Ultrastructural mitochondrial pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies. J Electron Microsc (Tokyo). 2008; 57(1):33-9. DOI: 10.1093/jmicro/dfm038. View

12.

Klement R, Champ C . Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. Cancer Metastasis Rev. 2014; 33(1):217-29. PMC: 3988521. DOI: 10.1007/s10555-014-9495-3. View

13.

Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo V . Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010; 9(22):4474-6. PMC: 3048045. DOI: 10.4161/cc.9.22.13954. View

14.

Patel A, Tirosh I, Trombetta J, Shalek A, Gillespie S, Wakimoto H . Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344(6190):1396-401. PMC: 4123637. DOI: 10.1126/science.1254257. View

15.

Artico M, Cervoni L, Celli P, Salvati M, Palma L . Supratentorial glioblastoma in children: a series of 27 surgically treated cases. Childs Nerv Syst. 1993; 9(1):7-9. DOI: 10.1007/BF00301926. View

16.

Brennan C, Verhaak R, McKenna A, Campos B, Noushmehr H, Salama S . The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-77. PMC: 3910500. DOI: 10.1016/j.cell.2013.09.034. View

17.

Deighton R, Le Bihan T, Martin S, Gerth A, McCulloch M, Edgar J . Interactions among mitochondrial proteins altered in glioblastoma. J Neurooncol. 2014; 118(2):247-256. PMC: 4048470. DOI: 10.1007/s11060-014-1430-5. View

18.

Woolf E, Scheck A . The ketogenic diet for the treatment of malignant glioma. J Lipid Res. 2014; 56(1):5-10. PMC: 4274070. DOI: 10.1194/jlr.R046797. View

19.

Ferreira L . Cancer metabolism: the Warburg effect today. Exp Mol Pathol. 2010; 89(3):372-80. DOI: 10.1016/j.yexmp.2010.08.006. View

20.

Mantis J, Centeno N, Todorova M, McGowan R, Seyfried T . Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies. Nutr Metab (Lond). 2004; 1(1):11. PMC: 529249. DOI: 10.1186/1743-7075-1-11. View